Hepatocellular Carcinoma, Liver Transplantation, Prognosis
Conditions
Brief summary
The study evaluated the protein expression levels of FK506-binding protein 12 (FKBP12) in hepatocellular carcinoma (HCC) and paracancerous tissues using immunohistochemistry (IHC). This study aimed to determine the role of FKBP12 in the outcome of liver transplantation recipients with HCC, especially those exceeding the Milan criteria. In addition, we explored how sirolimus administration affected LT recipients'prognosis depending on different FKBP12 expression, aiming to provide some advice for clinical sirolimus application after LT.
Interventions
GENETICFKBP12 expression
The expressions of FKBP12 were determined by immunohistochemistry (IHC) , and the immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (0-7) represented low expression levels, and IRS (8-12) represented high expression levels.
Sponsors
First People's Hospital of Hangzhou
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Inclusion criteria
* (1) pathologically confirmed HCC (2) full post-LT follow-up record
Exclusion criteria
* (1)sirolimus treatment less than 30 days or after tumor recurrence (2)died within 90 days (3)underwent multiple-organ transplantation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 2015.1.1-2021.1.1 | the length of months between surgery and the last follow-up or death |
Outcome results
None listed